SELECT PUBLICATIONS
Liu R, Weldon CB, Linehan E, Gordon N, Abbe T, Hennings M, James H, Katzel J, Ng C, Tomita M, Velotta JB, Ossowski S, Sakoda LC, Sprague SL, Dowling A, Beringer K, Ravelo A, Yu E, Trosman JR. Fostering a High-Functioning Team in Cancer Care Using the 4R Oncology Model: Assessment in a Large Health System and a Blueprint for Other Institutions. JCO Oncol Pract. 2022 Sep 30;:OP2200287. doi: 10.1200/OP.22.00287. [Epub ahead of print] PubMed PMID: 36178937.select
Weldon CB, Trosman JR, Liang SY, Douglas MP, Scheuner MT, Kurian A, Schaa KL, Roscow B, Erwin D, Phillips KA. Genetic counselors’ experience with reimbursement and patient out-of-pocket cost for multi-cancer gene panel testing for hereditary cancer syndromes. J Genet Couns. 2022 Jul 28;. doi: 10.1002/jgc4.1614. [Epub ahead of print] PubMed PMID: 35900261.select
Lin GA, Trosman JR, Douglas MP, Weldon CB, Scheuner MT, Kurian A, Phillips KA. Influence of payer coverage and out-of-pocket costs on ordering of NGS panel tests for hereditary cancer in diverse settings. J Genet Couns. 2022
Feb;31(1):130-139. doi: 10.1002/jgc4.1459. Epub 2021 Jul 7. PubMed PMID: 34231930; PubMed Central PMCID: PMC8893352.select
Martin JL, Azizoddin DR, Rynar LZ, Weber J, Oliver T, Weldon CB, Hauser JM. Comprehensive and Equitable Care for Vulnerable Veterans With Integrated Palliative, Psychology, and Oncology Care. Fed Pract. 2021 Aug;38(Suppl 3):S28-S35. doi: 10.12788/fp.0158. PubMed PMID: 34733093; PubMed Central PMCID: PMC8560117.select
Trosman JR, Weldon CB, Rapkin BD, Benson AB 3rd, Makower DF, Liang SY, Kulkarni SA, Perez CB, Lo SS, Krueger EA, Throckmorton AD, Gallagher C, Hoskins K, Schaeffer CM, Van Horn J, Schapira L, Ravelo A, Yu E, Gradishar WJ. Evaluation of the Novel 4R Oncology Care Planning Model in Breast Cancer: Impact on Patient Self-Management and Care Delivery in Safety-Net and Non-Safety-Net Centers. JCO Oncol Pract. 2021 Aug;17(8):e1202-e1214. doi: 10.1200/OP.21.00161. PubMed PMID: 34375560.select
Simon MA, Trosman JR, Rapkin B, Rittner SS, Adetoro E, Kirschner MC, O’Brian CA, Tom LS, Weldon CB. Systematic Patient Navigation Strategies to Scale Breast Cancer Disparity Reduction by Improved Cancer Prevention and Care Delivery Processes. JCO Oncol Pract. 2020 Dec;16(12):e1462-e1470. doi: 10.1200/JOP.19.00314. Epub 2020 Jun 23. PubMed PMID: 32574137; PubMed Central PMCID: PMC8462600.select
Kircher SM, Mulcahy M, Kalyan A, Weldon CB, Trosman JR, Benson AB. Telemedicine in Oncology and Reimbursement Policy During COVID-19 and Beyond. J Natl Compr Canc Netw. 2020 Sep 30;:1-7. doi: 10.6004/jnccn.2020.7639. [Epub ahead of print] PubMed PMID: 32998106.select
Liu R, Sundaresan T, Reed ME, Trosman JR, Weldon CB, Kolevska T. Telehealth in Oncology During the COVID-19 Outbreak: Bringing the House Call Back Virtually. JCO Oncol Pract. 2020 Jun;16(6):289-293. doi: 10.1200/OP.20.00199. Epub 2020 May 4. PubMed PMID: 32364826.select
Trosman JR, Douglas MP, Liang SY, Weldon CB, Kurian AW, Kelley RK, Phillips KA. Insights From a Temporal Assessment of Increases in US Private Payer Coverage of Tumor Sequencing From 2015 to 2019. Value Health. 2020 May;23(5):551-558. doi: 10.1016/j.jval.2020.01.018. Epub 2020 Mar 19. PubMed PMID: 32389219; PubMed Central PMCID: PMC7217867.select
Trosman JR, Weldon CB, Slavotinek A, Norton ME, Douglas MP, Phillips KA. Perspectives of US private payers on insurance coverage for pediatric and prenatal exome sequencing: Results of a study from the Program in Prenatal and Pediatric Genomic Sequencing (P3EGS). Genet Med. 2020 Feb;22(2):283-291. doi: 10.1038/s41436-019-0650-7. Epub 2019 Sep 10. PubMed PMID: 31501586; PubMed Central PMCID: PMC7004856.select
Gerhart J, Fitchett G, Lillis TA, Kuzel TM, Lo SS, Penedo F, Weldon CB, Diaz A. Brief spiritual well-being screening is nonlinearly related to psychological distress in ambulatory cancer patients. Psychooncology. 2018 Dec;27(12):2873-2876. doi: 10.1002/pon.4882. Epub 2018 Sep 27. PubMed PMID: 30189123.select
Phillips KA, Trosman JR, Weldon CB, Douglas MP. New Medicare Coverage Policy for Next-Generation Tumor Sequencing: A Key Shift in Coverage Criteria With Broad Implications Beyond Medicare. JCO Precis Oncol. 2018;2. doi: 10.1200/PO.18.00206. Epub 2018 Nov 8. PubMed PMID: 31073549; PubMed Central PMCID: PMC6503521.select
Trosman JR, Weldon CB, Gradishar WJ, Benson AB 3rd, Cristofanilli M, Kurian AW, Ford JM, Balch A, Watkins J, Phillips KA. From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor Sequencing. Value Health. 2018 Sep;21(9):1062-1068. doi: 10.1016/j.jval.2018.06.011. Epub 2018 Aug 3. PubMed PMID: 30224110; PubMed Central PMCID: PMC6374027.select
Phillips KA, Trosman JR, Deverka PA, Quinn B, Tunis S, Neumann PJ, Chambers JD, Garrison LP Jr, Douglas MP, Weldon CB. Insurance coverage for genomic tests. Science. 2018 Apr 20;360(6386):278-279. doi: 10.1126/science.aas9268. Epub 2018 Apr 19. PubMed PMID: 29674586; PubMed Central PMCID: PMC5991085.select
Phillips KA, Deverka PA, Trosman JR, Douglas MP, Chambers JD, Weldon CB, Dervan AP. Payer coverage policies for multigene tests. Nat Biotechnol. 2017 Jul 12;35(7):614-617. doi: 10.1038/nbt.3912. PubMed PMID: 28700544; PubMed Central PMCID: PMC5553867.select
Dervan AP, Deverka PA, Trosman JR, Weldon CB, Douglas MP, Phillips KA. Payer decision making for next-generation sequencing-based genetic tests: insights from cell-free DNA prenatal screening. Genet Med. 2017 May;19(5):559-567. doi: 10.1038/gim.2016.145. Epub 2016 Sep 22. PubMed PMID: 27657682; PubMed Central PMCID: PMC5362360.select
Trosman JR, Weldon CB, Douglas MP, Kurian AW, Kelley RK, Deverka PA, Phillips KA. Payer Coverage for Hereditary Cancer Panels: Barriers, Opportunities, and Implications for the Precision Medicine Initiative. J Natl Compr Canc Netw. 2017 Feb;15(2):219-228. doi: 10.6004/jnccn.2017.0022. Epub 2017 Feb 10. PubMed PMID: 28188191; PubMed Central PMCID: PMC5508568.select
Trosman JR, Weldon CB, Douglas MP, Deverka PA, Watkins JB, Phillips KA. Decision Making on Medical Innovations in a Changing Health Care Environment: Insights from Accountable Care Organizations and Payers on Personalized Medicine and Other Technologies. Value Health. 2017 Jan;20(1):40-46. doi: 10.1016/j.jval.2016.09.2402. PubMed PMID: 28212967; PubMed Central PMCID: PMC5319741.select
Weldon CB, Friedewald SM, Kulkarni SA, Simon MA, Carlos RC, Strauss JB, Bunce MM, Small A, Trosman JR. Radiology as the Point of Cancer Patient and Care Team Engagement: Applying the 4R Model at a Patient’s Breast Cancer Care Initiation. J Am Coll Radiol. 2016 Dec;13(12 Pt B):1579-1589. doi: 10.1016/j.jacr.2016.09.008. PubMed PMID: 27888945; PubMed Central PMCID: PMC5127438.select
Trosman JR, Carlos RC, Simon MA, Madden DL, Gradishar WJ, Benson AB 3rd, Rapkin BD, Weiss ES, Gareen IF, Wagner LI, Khan SA, Bunce MM, Small A, Weldon CB. Care for a Patient With Cancer As a Project: Management of Complex Task Interdependence in Cancer Care Delivery. J Oncol Pract. 2016 Nov;12(11):1101-1113. doi: 10.1200/JOP.2016.013573. Epub 2016 Oct 31. PubMed PMID: 27577619; PubMed Central PMCID: PMC5455414.select
Clain E, Trosman JR, Douglas MP, Weldon CB, Phillips KA. Availability and payer coverage of BRCA1/2 tests and gene panels. Nat Biotechnol. 2015 Sep;33(9):900-2. doi: 10.1038/nbt.3322. PubMed PMID: 26348951; PubMed Central PMCID: PMC4625918.select
Trosman JR, Weldon CB, Kelley RK, Phillips KA. Challenges of coverage policy development for next-generation tumor sequencing panels: experts and payers weigh in. J Natl Compr Canc Netw. 2015 Mar;13(3):311-8. doi: 10.6004/jnccn.2015.0043. PubMed PMID: 25736008; PubMed Central PMCID: PMC4372087.
Trosman JR, Weldon CB, Kelley RK, Phillips KA. Barriers to insurance coverage of next-generation tumor sequencing by U.S. payers. J Clin Oncol, 2014 (suppl; abstr 6545)
Murphy AM, Weldon CB, Trosman JR, Dupuy D, Schink JC, Ansell D, Simon MA. Does insurance mix impact utilization of published care practices and guidelines among breast imaging sites? J Clin Oncol, 2014 (suppl; abstr e17560)
Weldon CB, Trosman JR, Simon MA, Dupuy D, Roggenkamp B, Gradishar WJ, Murphy AM. Do breast cancer treatment and imaging providers follow hereditary breast and ovarian cancer risk screening guidelines? J Clin Oncol, 2014 (suppl; abstr e17626)
Abramowitz A, Trosman JR, Weldon CB, Schink JC, Simon MA. How are young women 18-24 counseled on hereditary breast and ovarian cancer (HBOC) testing? J Clin Oncol, 2014 (suppl; abstr 1546)
Weldon CB, Trosman JR, Roggenkamp B, Dupuy D, Gradishar WJ, Simon MA, Murphy AM. Do hospitals in a large metropolitan area utilize published breast cancer care practices and guidelines? J Clin Oncol, 2014 (suppl; abstr 1093)
Phillips KA, Sakowski JA, Trosman J, Douglas MP, Liang SY, Neumann P. The economic value of personalized medicine tests: what we know and what we need to know. Genet Med. 2013 Nov 14. doi: 10.1038/gim.2013. PMID: 24232413.
Trosman JT, Weldon CB. Models on Care Delivery. Chapter 17. Editors: Al Benson III, MD, A Chakravarthy, MD, Stanley Hamilton, MD. Cancers of the Colon and Rectum. A Multidisciplinary Approach to Diagnosis and Management Series. 288 pages Hardback. ISBN13 9781936287581
Rauscher GH, Murphy AM, Orsi JM, Dupuy DM, Grabler PM, Weldon CB. Beyond the mammography quality standards act: measuring the quality of breast cancer screening programs. AJR Am J Roentgenol. 2014 Jan; 202(1):145-51.
Trosman JR, Weldon CB, Schink JC, Gradishar WJ, and Benson AB. What do providers, payers and patients need from comparative effectiveness research on diagnostics? The case of HER2/Neu testing in breast cancer. Journal of Comparative Effectiveness Research, July 2013, Vol. 2, No. 4, Pages 461-477.
Schink JS, Trosman JR, Weldon CB, Siziopikou K, Gradishar WJ, Tsongalis GJ, Patel J, Benson AB, Perez E. Biomarker testing methods in breast, gastric and lung cancers – a benchmarking survey of NCI cancer centers. J Clin Oncol 31, 2013 (suppl; abstr e22093)
Weldon CB, Trosman JR, Benson AB, Tsongalis GJ, Siziopikou K, Gradishar WJ, Schink JS. Are oncologists involved in cancer biomarker decisions at their institutions? J Clin Oncol 31, 2013 (suppl; abstr 6617)
Siziopikou K, Weldon CB, Trosman JR, Gradishar WJ, Schink JS. What are NCI designated cancer centers using for breast cancer HER2 testing? J Clin Oncol 31, 2013 (suppl; abstr 626)
Weldon CB, Trosman JR, Schink JC. Cost of Cancer: There Is More to It Than Containing Chemotherapy Costs. Oncology. 2012, Vol. 26 No. 11
Weldon CB, Trosman JR, Gradishar WJ, Benson AB, Schink JC. Barriers to the Use of Personalized Medicine in Breast Cancer. Journal of Oncology Practice. 2012;8(4):24e-31e.
Weldon CB, Trosman JR, Dupuy DM, Roggenkamp B, Schink JC, Orsi JM, Murphy AM. Do patient tracking, follow-up, and referral practices contribute to breast cancer disparities in a large urban area? J Clin Oncol 30, 2012 (suppl; abstr 6120)
Dupuy DM, Orsi JM, Rauscher G, Murphy AM, Weldon CB, Trosman JR, Robinson PA, Marcus EA. Examining variation in mammography and breast cancer treatment quality. J Clin Oncol 30, 2012 (suppl; abstr e16531)
Trosman JR, Weldon CB, Dupuy DM, Roggenkamp B, Ganschow P, Schink JC, Murphy AM. Why do breast cancer programs fail to refer patients to genetic counseling upon obtaining family history? J Clin Oncol 30, 2012 (suppl; abstr 1553)
Weldon CB, Trosman JR, Dupuy DM, Roggenkamp B, Ganschow P, Schink JC, Murphy AM. Are breast cancer screening patients with family cancer history directed to genetic counseling/testing? Cancer Epidemiol Biomarkers Prev 2011;20(10 Suppl):A38.
Tsongalis GT, Weldon CB, Trosman JR, Gradishar WJ, Schink JC. Barriers to implementing primary HER2 FISH testing. J Clin Oncol 29: 2011 (suppl; abstr e16642)
Trosman JR, Weldon CB, Benson AB III, Gradishar WJ, Schink JC. “Oncology Medical Home” to address challenges in breast cancer care delivery. J Clin Oncol 29: 2011 (suppl; abstr e16641)
Doll KM, Weldon CB, Trosman JR, H Wetzel HH, Fallen TJ, Gradishar WJ, Schink JC. BRCA+ test result impact and timing on surgical treatment decisions for patients with breast cancer. J Clin Oncol 29: 2011 (suppl; abstr 626)
Schink JC, Doll KM, Weldon CB, Trosman JR, Wetzel HH, Fallen TJ, Gradishar WJ. Prophylactic oophorectomy for patients with breast cancer with BRCA results. J Clin Oncol 29: 2011 (suppl; abstr 1533)
Trosman JR, Van Bebber SL, Phillips KA. Health technology assessment and private payer’s coverage of personalized medicine. Am J Manag Care. 2011;17 Suppl 5:SP53-60. PMID:21711078
Weldon CB, Trosman JR, Dupuy DM, Alvarez RD, Murphy AM. Breast Cancer Care Improvement in an Urban Environment. AcademyHealth 2011 Annual Research Meeting.
Trosman JR, Weldon CB, Tsongalis GJ, Phillips KA, A Standardized BCR-ABL Monitoring Test: Assessment of Potential Adoption Impacts In Healthcare In the United States. Blood 2010 116:4754.
Trosman JR, Van Bebber S.L., Phillips K.A.. Coverage Policy Development for Personalized Medicine: Private Payer Perspective on Developing Policy for the 21-Gene Assay. Journal of Oncology Practice. September 2010 2010;6(5): 238-242. PMID:21197187
Schink J, Weldon CB, Trosman JR, Benson A, Gradishar W. Features of an “Oncology Medical Home”: Addressing Challenges in Cancer Care Delivery. Academy Health Annual Research Meeting, June 27-29, 2010, Boston, MA.
Van Bebber S, Trosman JR, Phillips K. One Size Does Not Fit All: Payers Use of Evidence Frameworks to Make Coverage and Policy Decisions. Academy Health Annual Research Meeting, June 27-29, 2010, Boston, MA.
Van Bebber SL, Trosman JR, Liang SY, Wang G, Marshall DA, Knight S & Phillips KA. Capacity building for assessing new technologies: approaches to examining personalized medicine in practice. Personalized Medicine (2010) 7(4), 427-439 PMID 21857867
Schink J, Weldon CB, Trosman JR, Benson A, Löffler A, Gradishar W. Care delivery barriers to personalized medicine in breast cancer. J Clin Oncol 28:15s, 2010 (suppl; abstr 6146)
Trosman JR, Weldon CB, Gradishar W, Schink J. Timing of genetic testing relative to breast cancer surgery. J Clin Oncol 28:15s, 2010 (suppl; abstr 666)